Icon (ICLR) Stock Forecast & Price Target

Compare

549 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ICLR Analyst Ratings

Moderate Buy

4 Buy

6 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Icon

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ICLR Stock 12 Month Forecast

Average Price Target

$137.22

▲(47.55% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Icon in the last 3 months. The average price target is $137.22 with a high forecast of $216.00 and a low forecast of $75.00. The average price target represents a 47.55% change from the last price of $93.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"74":"$74","217":"$217","109.75":"$109.8","145.5":"$145.5","181.25":"$181.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$216.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.2222222222222,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$137.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[74,109.75,145.5,181.25,217],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,178.59,181.46769230769232,184.34538461538463,187.22307692307692,190.10076923076923,192.97846153846154,195.85615384615386,198.73384615384614,201.61153846153846,204.48923076923077,207.3669230769231,210.24461538461537,213.1223076923077,{"y":216,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,178.59,175.40786324786325,172.2257264957265,169.04358974358973,165.86145299145298,162.67931623931622,159.4971794871795,156.3150427350427,153.13290598290598,149.95076923076923,146.76863247863247,143.5864957264957,140.40435897435896,{"y":137.2222222222222,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,178.59,170.62153846153848,162.65307692307692,154.6846153846154,146.71615384615384,138.74769230769232,130.77923076923076,122.81076923076924,114.84230769230768,106.87384615384616,98.90538461538462,90.93692307692308,82.96846153846154,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":199.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.21,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.59,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$216.00

Average Price Target$137.22

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Charles Rhyee

TD Cowen

$183→$120

Buy

29.03%

Upside

Upgraded

02/17/26

Icon plc: Accounting Probe Sell-Off Creates Compelling Value Despite Modest EPS Impact

Jamie Clark

Rothschild & Co Redburn

$226→$100

Hold

7.53%

Upside

Downgraded

02/17/26

Icon downgraded to Neutral from Buy at Rothschild & Co RedburnIcon downgraded to Neutral from Buy at Rothschild & Co Redburn

Jailendra Singh

Truist Financial

Hold

―

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), MiMedx Group (NASDAQ: MDXG) and Icon (NASDAQ: ICLR)

Eric Coldwell

Robert W. Baird

$217→$119

Buy

27.96%

Upside

Reiterated

02/13/26

Icon price target lowered to $119 from $217 at BairdIcon price target lowered to $119 from $217 at Baird

Michael Cherny

Leerink Partners

$105

Hold

12.90%

Upside

Downgraded

02/12/26

Icon downgraded to Market Perform from Outperform at LeerinkIcon downgraded to Market Perform from Outperform at Leerink

Michael Ryskin

Bank of America Securities

$195→$75

Sell

-19.35%

Downside

Downgraded

02/12/26

Icon downgraded to Underperform from Neutral at BofAIcon downgraded to Underperform from Neutral at BofA

Max Smock

William Blair

Buy

―

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Icon (NASDAQ: ICLR) and Perspective Therapeutics (NYSE MKT: CATX)

Sean Dodge

BMO Capital

$175→$100

Hold

7.53%

Upside

Reiterated

02/12/26

Icon price target lowered to $100 from $175 at BMO CapitalIcon price target lowered to $100 from $175 at BMO Capital

Ann Hynes

Mizuho Securities

$225→$216

Buy

132.26%

Upside

Reiterated

01/09/26

Icon price target lowered to $216 from $225 at MizuhoIcon price target lowered to $216 from $225 at Mizuho

Patrick B Donnelly

Citi

$200

Hold

115.05%

Upside

Reiterated

01/02/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Enovis (NYSE: ENOV) and Icon (NASDAQ: ICLR)

Luke Sergott

Barclays

$190→$200

Hold

115.05%

Upside

Reiterated

12/15/25

Barclays Sticks to Their Hold Rating for Icon (ICLR)

Elizabeth Anderson CFA

Evercore ISI

$220

Buy

136.56%

Upside

Reiterated

10/27/25

Evercore ISI Reaffirms Their Buy Rating on Icon (ICLR)

Dan Leonard

UBS

$240→$220

Buy

136.56%

Upside

Reiterated

10/24/25

Icon price target lowered to $220 from $240 at UBSIcon price target lowered to $220 from $240 at UBS

Casey Woodring

J.P. Morgan

$175

Hold

88.17%

Upside

Reiterated

10/23/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

David Windley

Jefferies

$220→$175

Hold

88.17%

Upside

Downgraded

09/08/25

Icon downgraded to Hold from Buy at JefferiesIcon downgraded to Hold from Buy at Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Charles Rhyee

TD Cowen

$183→$120

Buy

29.03%

Upside

Upgraded

02/17/26

Icon plc: Accounting Probe Sell-Off Creates Compelling Value Despite Modest EPS Impact

Jamie Clark

Rothschild & Co Redburn

$226→$100

Hold

7.53%

Upside

Downgraded

02/17/26

Icon downgraded to Neutral from Buy at Rothschild & Co RedburnIcon downgraded to Neutral from Buy at Rothschild & Co Redburn

Jailendra Singh

Truist Financial

Hold

―

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), MiMedx Group (NASDAQ: MDXG) and Icon (NASDAQ: ICLR)

Eric Coldwell

Robert W. Baird

$217→$119

Buy

27.96%

Upside

Reiterated

02/13/26

Icon price target lowered to $119 from $217 at BairdIcon price target lowered to $119 from $217 at Baird

Michael Cherny

Leerink Partners

$105

Hold

12.90%

Upside

Downgraded

02/12/26

Icon downgraded to Market Perform from Outperform at LeerinkIcon downgraded to Market Perform from Outperform at Leerink

Michael Ryskin

Bank of America Securities

$195→$75

Sell

-19.35%

Downside

Downgraded

02/12/26

Icon downgraded to Underperform from Neutral at BofAIcon downgraded to Underperform from Neutral at BofA

Max Smock

William Blair

Buy

―

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Icon (NASDAQ: ICLR) and Perspective Therapeutics (NYSE MKT: CATX)

Sean Dodge

BMO Capital

$175→$100

Hold

7.53%

Upside

Reiterated

02/12/26

Icon price target lowered to $100 from $175 at BMO CapitalIcon price target lowered to $100 from $175 at BMO Capital

Ann Hynes

Mizuho Securities

$225→$216

Buy

132.26%

Upside

Reiterated

01/09/26

Icon price target lowered to $216 from $225 at MizuhoIcon price target lowered to $216 from $225 at Mizuho

Patrick B Donnelly

Citi

$200

Hold

115.05%

Upside

Reiterated

01/02/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Enovis (NYSE: ENOV) and Icon (NASDAQ: ICLR)

Luke Sergott

Barclays

$190→$200

Hold

115.05%

Upside

Reiterated

12/15/25

Barclays Sticks to Their Hold Rating for Icon (ICLR)

Elizabeth Anderson CFA

Evercore ISI

$220

Buy

136.56%

Upside

Reiterated

10/27/25

Evercore ISI Reaffirms Their Buy Rating on Icon (ICLR)

Dan Leonard

UBS

$240→$220

Buy

136.56%

Upside

Reiterated

10/24/25

Icon price target lowered to $220 from $240 at UBSIcon price target lowered to $220 from $240 at UBS

Casey Woodring

J.P. Morgan

$175

Hold

88.17%

Upside

Reiterated

10/23/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

David Windley

Jefferies

$220→$175

Hold

88.17%

Upside

Downgraded

09/08/25

Icon downgraded to Hold from Buy at JefferiesIcon downgraded to Hold from Buy at Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Icon

3 Months

xxx

Success Rate

22/41 ratings generated profit

Average Return

+3.00%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.66% of your transactions generating a profit, with an average return of +3.00% per trade.

1 Year

Eric ColdwellRobert W. Baird

Success Rate

22/41 ratings generated profit

Average Return

+6.51%

a rating ―

Copying Eric Coldwell's trades and holding each position for 1 Year would result in 53.66% of your transactions generating a profit, with an average return of +6.51% per trade.

2 Years

xxx

Success Rate

24/41 ratings generated profit

Average Return

+8.05%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.54% of your transactions generating a profit, with an average return of +8.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ICLR Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ICLR has received 6 Buy Ratings, 11 Hold Ratings, and 1 Sell Ratings. ICLR average Analyst price target in the past 3 months is 137.22.

Each month's total comprises the sum of three months' worth of ratings.

ICLR Financial Forecast

ICLR Earnings Forecast

Next quarter’s earnings estimate for ICLR is $3.27 with a range of $2.77 to $3.43. The previous quarter’s EPS was $3.31. ICLR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ICLR has Performed in-line its overall industry.

ICLR Sales Forecast

Next quarter’s sales forecast for ICLR is $2.00B with a range of $1.97B to $2.02B. The previous quarter’s sales results were $2.04B. ICLR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ICLR has Performed in-line its overall industry.

ICLR Stock Forecast FAQ

What is ICLR’s average 12-month price target, according to analysts?

Based on analyst ratings, Icon plc’s 12-month average price target is 137.22.

What is ICLR’s upside potential, based on the analysts’ average price target?

Icon plc has 47.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ICLR a Buy, Sell or Hold?

Icon plc has a consensus rating of Moderate Buy which is based on 4 buy ratings, 6 hold ratings and 1 sell ratings.

What is Icon plc’s price target?

The average price target for Icon plc is 137.22. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $216.00 ,the lowest forecast is $75.00. The average price target represents 47.55% Increase from the current price of $93.

What do analysts say about Icon plc?

Icon plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of ICLR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Icon (ICLR) Stock Forecast & Price Target

ICLR Analyst Ratings

ICLR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Icon

ICLR Analyst Recommendation Trends

ICLR Financial Forecast

ICLR Earnings Forecast

ICLR Sales Forecast

ICLR Stock Forecast FAQ

Detailed List of Analyst Forecasts